SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-128446
Filing Date
2023-12-22
Accepted
2023-12-22 06:15:44
Documents
12
Period of Report
2023-12-20
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2333503d1_8k.htm   iXBRL 8-K 24307
  Complete submission text file 0001104659-23-128446.txt   195627

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nbse-20231220.xsd EX-101.SCH 3048
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbse-20231220_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbse-20231220_pre.xml EX-101.PRE 22381
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2333503d1_8k_htm.xml XML 3226
Mailing Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219
Business Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219 412-763-3350
NeuBase Therapeutics, Inc. (Filer) CIK: 0001173281 (see all company filings)

IRS No.: 465622433 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35963 | Film No.: 231507112
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)